SLC5A2 and type 2 diabetes mellitus: Another SGLT2 inhibitor, sotagliflozin, has been studied for its cardiovascular effects in patients with T2DM and chronic kidney disease with or without albuminuria for a median period of 15.9 months by Bhat et al. in 2021 [24].